BACKGROUND: Angiogenesis is important in health and several disease states. CD105 is a proliferation-associated and hypoxia-inducible transmembrane protein abundantly expressed in angiogenic endothelial cells. CD105 is a receptor for transforming growth factors (TGF)-beta1 and -beta3. The exact mechanisms for CD105 regulation of vascular development have not been fully elucidated. MATERIALS AND METHODS: In this study, an antisense approach to create a murine and a human stably transfected endothelial cell line expressing a reduction in CD105 protein was used. RESULTS: We showed that inhibition of CD105 in cultured murine and human endothelial cells enhanced the ability of TGF-beta1 to suppress growth and migration, and influenced TGF-beta1 promoter activity. TGF-beta1 not only reduced the length of the capillary-like structures, but also caused mortality in CD105-deficient murine antisense cells compared to control cultures. To determine whether CD105 affected TGF-beta1-induced gene expression, a luciferase assay in transiently transfected cells with p3TP-Lux promoter constructs was performed. Both murine and human antisense transfectants showed a significant increase in p3TP-Lux promoter activity. Further studies on the functional importance of CD105 was undertaken in irradiated normoxic and hypoxic cells. The levels of pro- and anti-apoptotic markers were also evaluated. There was an increase in pro-apoptotic marker (p53), but a reduction in anti-apoptotic marker (Bcl-2) in CD105-deficient cells. CONCLUSION: These results provide direct evidence that CD105 antagonises the inhibitory effects of TGF-beta1 on human and murine vascular endothelial cells and that normal cellular levels of CD105 are required for the formation of new blood vessels.
BACKGROUND: Angiogenesis is important in health and several disease states. CD105 is a proliferation-associated and hypoxia-inducible transmembrane protein abundantly expressed in angiogenic endothelial cells. CD105 is a receptor for transforming growth factors (TGF)-beta1 and -beta3. The exact mechanisms for CD105 regulation of vascular development have not been fully elucidated. MATERIALS AND METHODS: In this study, an antisense approach to create a murine and a human stably transfected endothelial cell line expressing a reduction in CD105 protein was used. RESULTS: We showed that inhibition of CD105 in cultured murine and human endothelial cells enhanced the ability of TGF-beta1 to suppress growth and migration, and influenced TGF-beta1 promoter activity. TGF-beta1 not only reduced the length of the capillary-like structures, but also caused mortality in CD105-deficient murine antisense cells compared to control cultures. To determine whether CD105 affected TGF-beta1-induced gene expression, a luciferase assay in transiently transfected cells with p3TP-Lux promoter constructs was performed. Both murine and human antisense transfectants showed a significant increase in p3TP-Lux promoter activity. Further studies on the functional importance of CD105 was undertaken in irradiated normoxic and hypoxic cells. The levels of pro- and anti-apoptotic markers were also evaluated. There was an increase in pro-apoptotic marker (p53), but a reduction in anti-apoptotic marker (Bcl-2) in CD105-deficient cells. CONCLUSION: These results provide direct evidence that CD105 antagonises the inhibitory effects of TGF-beta1 on human and murine vascular endothelial cells and that normal cellular levels of CD105 are required for the formation of new blood vessels.
Authors: Nathan M Solbak; Bryan J Heard; Yamini Achari; May Chung; Nigel G Shrive; Cyril B Frank; David A Hart Journal: Inflamm Res Date: 2015-06-20 Impact factor: 4.575
Authors: Monique E De Paepe; Chintan Patel; Amy Tsai; Sravanthi Gundavarapu; Quanfu Mao Journal: Am J Respir Crit Care Med Date: 2008-04-17 Impact factor: 21.405
Authors: Gavin M Mason; Emma Poole; J G Patrick Sissons; Mark R Wills; John H Sinclair Journal: Proc Natl Acad Sci U S A Date: 2012-07-23 Impact factor: 11.205
Authors: Anna A Egorova; Sofia V Shtykalova; Marianna A Maretina; Dmitry I Sokolov; Sergei A Selkov; Vladislav S Baranov; Anton V Kiselev Journal: Pharmaceutics Date: 2019-06-06 Impact factor: 6.321